Glutamate drugs and pharmacogenetics of OCD: a pathway-based exploratory approach.
Baltimore, United States. In Expert Opin Drug Discov, 2013
Furthermore, recent genetic epidemiology research findings are presented with a focus on the positional candidate genes SLC1A1 (a glutamate transporter), ADAR3 (an RNA-editing enzyme), RYR3 (a Ca(2+) channel), PBX1 (a homeobox transcription factor) and a GWAS candidate gene, DLGAP1 (a protein interacting with post-synaptic density).
Aicardi-Goutières syndrome: clues from the RNase H2 knock-out mouse.
Kiel, Germany. In J Mol Med (berl), 2013
AGS-causing mutations have also been found in the genes of the 3'-exonuclease TREX1, the dNTP triphosphatase SAMHD1, as well as the RNA-editing enzyme ADAR1, defining defects in nucleic acid metabolism pathways as a common hallmark of AGS pathology.
Astrocytic 5-HT(2B) receptor as in vitro and in vivo target of SSRIs.
Shenyang, China. In Recent Pat Cns Drug Discov, 2012
Chronic treatment with fluoxetine upregulates gene expression of cPLA₂, ADAR2, GluK2 and 5-HT(2B) receptors, and RNA editing of the later two in cultured astrocytes and in astrocytes obtained by fluorescence-activated cell sorting of cells from fluoxetinetreated mice.
A new function for the RNA-editing enzyme ADAR1.
Philadelphia, United States. In Nat Immunol, 2009
This RNA-editing enzyme is now shown to be involved in hematopoiesis, where it acts to suppress interferon signaling and to block premature apoptosis.